Food and Drug Administration (FDA) has approved seven biosimilars for pegfilgrastim, the active ingredient in the reference product Neulasta (developed by Amgen). Pegfilgrastim is a PEGylated form of granulocyte colony-stimulating factor used to reduce the risk of febrile neutropenia in patients undergoing myelosuppressive chemotherapy.
The FDA’s consideration of a biosimilar drug could open up biologic drug research. Learn how you can innovate with our PEGylation products!
In November 2015, the Food and Drug Administration approved the use of Amgen’s pegfilgrastim (Neulasta) to increase the survival of people acutely exposed to high-dose radiation that damages the bone marrow, which will improve access to the drug in the event of a public health emergency such as a nuclear power plant accident or terrorist […]
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor analog filgrastim. It serves to stimulate the level of white blood cells. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours). Pharma Companies & PEGylated Drug Development Multiple major pharma companies have been busy […]
Cart : 0
Account